AbbVie reports data. AbbVie stock trades 0.10 percent above Xetra close of EUR 254.40
Published on 10/25/2026 at 17:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSClinical data and market timing
- On October 19, 2026, AbbVie reported 30.2 percent endoscopic remission for ABBV-466 at Week 12.
- AbbVie stock trades in weekend trading at Lang & Schwarz at EUR 254.65 at 5:30 p.m. CEST on October 25, 2026, 0.10 percent above the Xetra close of October 23, 2026.
- The next Xetra session is scheduled for October 26, 2026.
On October 19, 2026, AbbVie reported data from the Phase 2a TARGET-CD study showing that investigational ABBV-466 achieved higher endoscopic remission rates than either monotherapy in patients with moderate to severe Crohn's disease, according to PR Newswire. At Lang & Schwarz, AbbVie stock trades in weekend trading at EUR 254.65 at 5:30 p.m. CEST on October 25, 2026, 0.10 percent above the Xetra close of October 23, 2026 at EUR 254.40.
Market context: Market report S&P 500.
The week in figures
The Xetra close on October 23, 2026 was EUR 254.40. The Lang & Schwarz weekend price is EUR 254.65, or 0.10 percent above that reference. The quote showed a bid of EUR 254.40 and an ask of EUR 254.90.
The further course of weekend trading at Lang & Schwarz until 7:00 p.m. CET/CEST is shown by the continuously updated real-time quote of AbbVie stock.
Chronology of the week
On October 19, AbbVie said ABBV-466 produced endoscopic remission in 30.2 percent of patients at Week 12, compared with 21.3 percent for anti-IL-23 p19 monotherapy and 18.0 percent for anti-?4?7 monotherapy. At Week 24, the rate was 40.5 percent for ABBV-466, compared with 22.4 percent and 20.0 percent for the two monotherapy groups, respectively. The findings were published by PR Newswire.
On October 20, AbbVie announced a multi-year partnership with McLaren Racing. The company said it will donate $10,000 to global charities for every 10 Constructors' Championship points earned by McLaren, as reported by PR Newswire.
Dates of the coming week
The next Xetra session is scheduled for October 26, 2026. AbbVie has said ABBV-466 remains investigational and that its safety and efficacy have not been established by regulatory authorities.
